NCT01692925View on ClinicalTrials.gov

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Congenital Bleeding DisorderHaemophilia A
Interventions
DRUG

turoctocog alfa

Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.

DRUG

turoctocog alfa

Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.

Trial Locations (5)

1006

Novo Nordisk Investigational Site, Riga

10249

Novo Nordisk Investigational Site, Berlin

28046

Novo Nordisk Investigational Site, Madrid

50400

Novo Nordisk Investigational Site, Kuala Lumpur

60590

Novo Nordisk Investigational Site, Frankfurt/M.

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY